



Index

- A**
- Abercrombie, Michael, 48
- Acquired characteristics
inheritance of, 33, 259–262
multigenerational
heritability, 46
- Adenine, methylation of, 89
- Adenomas, 254–255
- The Adventure of Silver Blaze*
(Conan-Doyle), 129
- Affinity assays, 172, 172f,
178–180
- Aging, DNA methylation
association with, 10–11
- Aguirre-Ghiso, Julio, 246
- Allelic skewing, 316
- Allis, Charles David, 72,
108–110, 310
- All-*trans* retinoic acid (ATRA),
318–319
- a (nonagouti)* locus, 145–146, 146f
- ALSPAC (Avon Longitudinal
Study of Parents and
Children), 290–291
- Alternative splicing, 96, 187,
189
- Altman, Sidney, 104
- Analytical approaches, 222
- Androgenones, 70
- Aniline, 155
- Animaliculus, 28, 310
- Animal models, 221, 273–277,
275f
- APC* mutation, 247
- APOBEC enzymes, 253
- Aquinas, St. Thomas, 22–23
- Arabidopsis*, functional RNAs
in, 102
- Argaw-Denboba, Ayele, 303
- Argonaute protein, 101–102
- Aristotle, 19–22, 260
- Ascorbic acid, 205
- Asthma, 151–152
- ATAC-seq (assay for
transposase-accessible
chromatin using
sequencing), 182–183,
195, 217, 222, 313, 317
- ATRA (all-*trans* retinoic acid),
318–319
- Avon Longitudinal Study of
Parents and Children
(ALSPAC), 290–291
- Axin1^{Flu}, 298–299
- Axin1* locus, 277
- 5-azacytidine (5azaC),
234–235, 255
- 5-aza-2'-deoxycytidine
(5-Aza-dC), 233, 238
- B**
- Baden Aniline and Soda
Factory (BASF), 155
- Baeyer, Adolf von, 155
- Barker, David, 6–7, 9, 204,
281–284
- Barlow, Denise, 70–71
- Barr, Murray, 62–64
- Barr body, 64, 127
- Barsh, Greg, 145
- Bateson, William, 33–34
- Baylin, Steve, 233
- BDT (bromo and extra-
terminal) inhibitor, 257
- BeadArray, 173
- Beckwith–Wiedemann
syndrome (BWS), 203
- Benedict, Bill, 234
- Bergman, Steven, 103
- Bernstein, Bradley (Brad), 11,
194–195, 251
- Bertram, Ewart (Mike), 62–63
- Bestor, Tim, 72, 85
- β -globin genes, 112, 229
- β -globin locus control region
(LCR), 165–166
- BET (bromodomain and
extraterminal motif)
proteins, 12
- Beutler, Ernest, 65
- Bickmore, Wendy, 124, 185
- Biomarkers
development of, 219–220
DNA methylation, 315–316,
329
epigenetic changes in cancer
used as, 253–255
- Biotin-labeled nucleotide
triphosphates (biotin-
NTPs), 188
- Bird, Adrian, 71, 74, 82–83,
173, 231–232, 330
- Bisulfite sequencing, 193, 222,
317
- Bivalent chromatin domains,
194–195
- Blood count
complete blood count
(CBC), 330
differential, 210–211
- Blood leukocyte DNA
methylation, 215
- Blumenbach, J.F., 30–31
- Bonner, John Tyler, 228
- Boveri, Theodor, 34, 122
- Boveri-Sutton chromosome
theory, 122
- Boyer, Herbert, 59, 61, 90, 103
- BRAF*, 238–240, 239f
- Brenner, Sydney, 67, 267
- Brink, Alexander, 265
- Broad domain, 191–192
- Bromodomain and
extraterminal motif
(BET) proteins, 12
- Bromodomains, 109, 257

- Brown, Carolyn, 103–104
BWS (Beckwith–Wiedemann syndrome), 203
- C**
- 3C (chromosome conformation capture), 123–124, 184
4C (chromosome conformation capture–on–ChIP), 184
5C (chromosome conformation capture carbon copy), 184–185
CADD (Combined Annotation-Dependent Depletion) score for noncoding loci, 327
Caenorhabditis elegans, 111, 267–268
Calcitonin, 230–231
Calico cats, 147–148
Cancer
 colorectal, 246–248, 253–255
 dormancy, 245–246
 gliomas, 11, 251
 as a paradigm of human epigenetic disease, 257
 promyelocytic leukemia (PML), acute, 318–319, 320f
 therapies directed at transcriptional regulatory mechanisms, 255–257
Cancer epigenetics, 225–258
 biomarkers, 253–255
 CpG island hypermethylation, 233, 238–240
 definition of, 235, 240, 244
 deliveries of field, 257–258
 diet and colorectal cancer, 246–248
 dysregulation of epigenetic regulators, 240
 epigenetic dysregulation not attributable to mutations, 244–252
 epigenome influences on the mutability of the genome in cancer, 252–253
 field effects, 249–252
 gliomas, 11, 251
 global DNA hypomethylation, 231, 236–238
 historical perspective, 71–72, 225–235
 interventions, 12
 mutation as the primary event, 240–244
 mutation of transcriptional regulators, 241–242
 mutations causing local changes of epigenetic regulation, 243
 mutations causing metabolic effects with secondary epigenetic effects, 242
 therapies, 318–319
 viral effects, 248–249
Cancer epigenetics, history of discovery of pharmacological inhibitors of DNA methylation, 233–235
 Huxley, 226–227
 modern rebirth, 227–233
 Ruth Sager, 230
 term use in 1927, 225
Cancer genomics, 161
Cardiac channelopathies, 156
Cardiovascular disease, 282
Cardoso, Wellington, 150–151, 153
Caro, Heinrich, 155
Carrell, Douglas, 299–300
Cattanach, Bruce, 144
Causation, reverse, 209–210
cDNA (complementary DNA), 179
Cech, Thomas, 104
Cell count QTL (ccQTL), 159, 161
Cell fate
 decisions and epigenetics studies, 149, 152
 molecular influences on, 288–289
 transcription factors, 131, 134, 218
 variation in, 314–315
Cell signaling pathways, 134
Cell subtype composition
 DNA methylation, effects on, 139–142, 141f, 157–159, 158f, 254, 276
 in DOHaD models, 277
 epigenetic assay use to report changes, 214–215
 immune system, 288
 knowing of the tissue studied, 221
 proportional composition, 210–212, 214–215
 single-cell transcriptional studies, 161
Cell type, defining, 330
Cellular genomics
 approach to understanding human disease pathogenesis, 161
 overview, 160–161
 studies of human disease, 223
Cellular memory
 cooperative system for, 136–137
 epigenetic properties as, 203
Cellular models
 of phenotypes and diseases, 152–154
 of reprogramming, 159–160
Cellular reprogramming
 cellular models, 159–160
 chromatin changes, 161
 epigenetic events in diseases, 214
 maternal-fetal exposures during pregnancy, 290
 model of epigenetic properties of cells, 152–154, 156, 276
 morphological properties of cells as, 155
 transcription factors, 218
CENPA protein, 115, 118
Centromeres, 115–116
Cervical clear cell adenocarcinoma (CCA), 273
Chandler, Vicki, 265
Chaperones, 116, 118
Chen, Zhu, 319
CHG methylation, 84
Chinese famine, 261, 281
ChIP (chromatin immunoprecipitation), 6, 166, 181, 185–186, 196
ChIP-on-chip, 166, 194–195
ChIP-seq, 181, 183–184, 186, 193, 195, 196, 317

- Chlamydomonas*, 52–54, 89, 230
ChLC (chromatin immunocleavage), 181
Christensen, Brock, 139–140
Chromatin
DNA packaging by histones, 6
epigenomics assays of components, 181–185
histone variants, 114–118
nucleosomal positioning, 111–114
open, 182–183, 190
post-translational modifications of, 107–111, 108t
variability of, 106–128
Chromatin assays, 196, 222
Chromatin-associated RNAs, 96
Chromatin immunocleavage (ChIC), 181
Chromatin
immunoprecipitation (ChIP), 6, 166, 181, 185–186, 196
Chromatin insulation, 118–121, 184
Chromatin looping, 122–126, 184–185, 222
Chromatin QTL (cQTL), 221
Chromodomains, 109–111
Chromosomal imprinting. *See also*
Genomic imprinting
Crouse, 53, 56, 67
in *Sciara*, 67, 68f
Chromosomal theory, 34
Chromosome breakage, 237–238, 252
Chromosome conformation capture (3C), 123–124, 184
Chromosome conformation capture carbon copy (5C), 184–185
Chromosome conformation capture-on-ChIP (4C), 184
Chromosome Marker (Lewis and John), 53
Chromosome territory, 122–123
CIBERSORT, 198, 211
Cigarette smoking, 9–10
Ciliopathies, 156
CIMP (CpG island methylator phenotype), 71–72, 233, 238–240
cis expression quantitative trait locus (eQTL), 157, 158f, 159, 216
cis methylation quantitative trait locus (meQTL), 213
Clark, Susan, 173
Clustered regularly interspaced short palindromic repeats (CRISPR) system, 90
Cohen, Barak, 132
Cohort size, 209
Colocalization, 196–198
Colorectal cancer, 246–248, 253–255
Combined Annotation-Dependent Depletion (CADD) score for noncoding loci, 327
Complementary DNA (cDNA), 179, 187
Complete blood count (CBC), 330
Compound microscope, history of development, 26–27
Conan-Doyle, Arthur, 129
Confounders, harvesting in epigenetic assays, 214–217
Consumer products, epigenetic, 13–14, 309
Co-transcriptional splicing, 96
Covalent modifications, of RNA, 93–94, 180
CpG epigenetic clock, 10–11
CpG island methylator phenotype (CIMP), 71–72, 233, 238–240
CpG islands
annotation, 169–170
defined, 169, 231–232
density of CG dinucleotides in, 172f
methylation, 71–73, 165–167, 193, 231–233, 238–240
overview, 71–73, 166–170
CpG island shores, 193
CpG methylation, 71–73, 165–167, 193, 231–233, 238–240
cQTL (chromatin QTL), 221
Creodes, 142, 149, 153, 159, 301–302, 315, 330
CRISPR, 319–320
Critique of Judgment (Kant), 31
Crouse, Helen, 53, 56, 67
Cryptococcus neoformans, 86–87
CTCF, 11, 73, 120–121, 121f, 124, 126, 130, 190, 251
CUT&RUN, 181, 186
CUT&Tag, 323
Cytoplasmic inheritance, 47
D
DamID, 183–184, 192
D'Armata, Salvino, 24
Darwin, Charles, 32, 260, 269, 293
Data torturing, 284, 326
da Vinci, Leonardo, 23, 23f
Deamination, 167, 168f
Deconvolution, 198, 199, 211–212, 216, 221
de Graaf, Regnier, 26
Dekker, Job, 123–124, 184
Delbrück, Max, 47, 49
Demethylases, 93–94
Demethylation, 87–89, 297
de Rooij, Susanne, 285
DES (diethylstilbestrol), 272–273
Determinism, epigenetic, 301–302
Development
environmental influences during, 204
as a landscape of branching valleys, 40
role of retinoic acid in lung development, 150–152
Developmental genetics
emergence of, 32–36
epigenetic landscape, 43
Gluecksohn-Waelsch, Salome, 44
Developmental origins of health and disease (DOHAD)
animal models, 273–277, 275f
Darwin as laying foundation for, 33

- Developmental origins of health and disease (DOHaD) (*Continued*)
David Barker, 281–284
dietary change during pregnancy, 9
discordance of
epidemiologists concerning, 282–285
epigenetic association studies, 286–287
famines and human diseases, 278–281
inspiration behind field of, 7
intergenerational inheritance, 263
metastable epialleles, 277
model within the life course, 287–289
perturbations in early life, 149–151
unintended negative consequences of research, 305–306
window of susceptibility, 204
Diabetes mellitus, type 2, 148
Diagnostic histopathology, 155
Dicer, 48, 310
Dictyostelium discoideum, 228–229
Diet
change during pregnancy, 9
colorectal cancer in mice, 246–248
famines and human disease, 278–281
influence of, 204–206
Diethylstilbestrol (DES), 272–273
Differential blood count, 210–211
Differentially methylated regions (DMRs), 99
Differentiation, epigenomic pattern transitions in, 193–195
Directional RNA sequencing assay, 187
Disease
cellular genomic studies, 223
DNA methylation profiles, 330
DOHaD (*see* Developmental origins of health and disease),
epigenetic mechanisms of, 201–223, 202t
epigenetic therapies, 318–321
molecular genomic assays, 315–316
Disease risk
developmental origins of health and disease (DOHaD), 149–151
environmental factors in, 148
Disteche, Christine, 126
DMRs (differentially methylated regions), 99
DNA adenine methyltransferase identification (DamID), 183–184, 192
DNA-binding proteins, 92
DNA methylation. *See also specific examples*
affinity-based DNA methylation assays, 172, 172f
age associations, 10–11
assays, 171–179
biomarkers, 253
blood cell subtype proportion variability, 254
in cancer field effects, 250–251
cell subtype effects on, 139–142, 141f, 157, 160
cell subtype proportions and, 210–212, 214–215, 276
changes as cells differentiate, 193–194
changes in development, 204
CpG island hypermethylation, 233, 238–240
CpG islands, 71–73, 165–167, 193, 231–233, 238–240
default state, 192
as digital (binary) readout of the alleles tested, 197
discovery, 6
environmental factors, 205
epigenome-wide association study (EWAS), 206–208
genetic effects on, 212–214
genome-wide studies, 95
global DNA hypomethylation, 231, 236–238
haplotypes, 322–323, 324f–325f, 326
in human DOHaD cohorts, 285–286
at IAP element, 9
intermediate, 197
maintenance, 54–55, 57, 59, 62, 65, 83, 267
5-methylcytosine cycle, 83–89
and the modern rebirth of cancer epigenetics, 227–233
molecular memory by, 54–55, 59, 62
ontogeny of in mammals, 51
paternal effects, 291–292
pattern in cigarette smokers, 10
in peripheral blood leukocytes, 317
PMDs (partially methylated domains), 192
in restriction-modification systems, 90
retrotransposons, 298–299
RNA-directed DNA methylation (RdDM), 98–99, 267
signatures, 315
smoking-associated changes in, 207, 220
in sperm, 299–300
stability of modification, 10
tissue differentially methylated region (tDMR), 165
DNA methylation signatures (episignatures), 330
DNA methyltransferases (DNMTs)
cancer epigenetics, 237–238
CXXC domains, 92
inhibitors, 233, 238, 256
mutations, 72, 236–238
overview, 85–87

- DNA microarrays, 6
DNA mutation repair system, 252
DNA repair, 167, 168f
DNase, 111–112, 182, 190, 235
DNA sequence variation
 DNA methylation, influence on, 216
 epigenetic modification, 199
 polymorphism, 212–214
 revealing interactions with variability, 221–222
 single-nucleotide polymorphisms (SNPs), 173, 179, 212–213
 using epigenetic assay to report effects, 215–217, 219
DNase-seq, 182, 317
DNA structure, variation of, 90–92, 91f, 179–180
DNA variability, 83–92
DNMTs. *See* DNA methyltransferases
Dobzhansky, Theodosius, 38–39
DOHaD. *See* Developmental origins of health and disease
Dormancy, 245–246
DpnI, 183
Drainage, epigenetic/ inherited, 43–44
Drosophila
 chromatin insulators, 119
 DNA methylation, 87
 Morgan's use as model organism, 35
 piRNAs, 99
 Polycomb-response element (PRE), 111, 128
 polytene chromosomes, 124
 position-effect variegation, 127, 143–144, 314
 transgenerational memory, 268–270
dsRNA, 268
Dubos, René, 273–274, 278, 304, 326
Dunn, L.C., 44
Dutch Hunger winter, 279–281, 284–285
DXZ4, 126
Dyes, 154–155
E
 Early-life events, 278, 287
 EBV (Epstein–Barr virus), 249
 ECREE (extraordinary claims require extraordinary evidence) aphorism, 262, 270
 EDCs (endocrine-disrupting chemicals), 272
 Edman degradation, 107
 Ehrlich, Melanie, 227–230
 Elemente der exakten Erblichkeitslehre (Johannsen), 34
 Embryologists, schism with geneticists, 36–38
 Embryology
 history of study, 17–38, 23f
 schism between embryologists and geneticists, 36–38
 Emerging technologies, 321–326
 ENCODE (ENCyclopedia of DNA Elements) Project, 97
 Endocrine-disrupting chemicals (EDCs), 272
 Enhancer-blocking assay, 119–120
 Enhancer landscape, 248
 Enhancer of variegation (E(var)) genes, 127
 Enhancer RNAs (eRNAs), 190–191, 213
 Enhancers, 189–194
 Environmental influences
 candidates for mediating, 204–206
 window of susceptibility, 204
 Eosin, 155
 Ephrussi, Boris, 47–48
 Epialleles, 144–146, 146f, 267, 277, 299
 Epigenesis
 Blumenbach advocacy for model, 31
 Kant on, 31
 preformationism *versus*, 310
 reaction theory, 35
 rise of model, 29–32
 Waddington, 73–74, 149, 156, 225
 Wolff's defense of, 29–30
 word coined by Harvey, 25
 Epigenetic (term)
 back-translation of, 73
 defined, 81
 Nanney, 47–49, 51, 62, 74–75, 76f, 156
 Pugh and Holliday, 56–59, 56f, 73
 resurrection of term, 51, 52f
 Riggs, 61–62
 self-contradictory, 78
 Waddington, 39, 48–49
 Epigenetic association study
 genetic variation influence on results, 286–287
 in human cohorts, 285–287
 problem with interpretability, 7–8
 Epigenetic association study design and execution
 analytical approaches, 222
 assay choice, 222
 cell subtype composition, 221
 cross-sectional or longitudinal, 220
 goal of study, 219–220
 interactions with DNA sequence variability, 221–222
 tissue sampling, 220–221
 verification and replication, 223
 Epigenetic clock CpGs, 10–11
 Epigenetic determinism, 301–302
 Epigenetic editing, 110
 Epigenetic landscape, 38, 40–46, 62, 74, 76f, 142, 144, 149, 153, 156, 161, 247, 301, 311, 322, 330
 Epigenetic mechanisms of disease
 environmental exposures mediated through transcriptional regulatory mechanisms, 204
 genetic mutation as primary event, 203

- Epigenetic mechanisms of disease (*Continued*)
molecular candidates for mediating environmental influences, 204–206
overview, 201–203, 202t
- Epigenetic priming, 252
- Epigenetic properties as those of cells, 139–162
metastable epialleles, 144–146, 146f
position effect variegation, 143–144
retinoic acid signaling, 150–152
X-chromosome inactivation, 146–147
- Epigenetic regulators, necessary properties of, 81–83
- Epi+genetic regulatory mechanisms, 148
- Epigenetics
ambiguity, 1–2
challenges, 326–329
consumer products, 148–149
definitions, 1–3, 51–79, 81–83
excitement about, 3–5
foundations of modern, 5–7
fundamental questions in, 329–331
future research, 311–315
major paradigms in, 7–11
problems that have emerged in, 12–14
from research to clinical intervention, 12
resurrection of the idea of, 156
- Epigenetics (term)
first use in context of cancer, 225
Huxley's use of, 226
- Epi+genetics back-translation, 82, 94
- Epigenetics definition
biochemical insights into, 136–137
Bird, 74
cell-centric, 143
epi+genetics definition, 73, 75, 76f, 77, 82–83, 109, 136
history of, 51–79
major, disconnected definitions, 74–75
multigenerational memory, 75, 76f
problem of multiple, 75–78
Riggs, 74–75
solution to multiple, 78–79
- Epi+genetics definition, 73, 75, 76f, 77, 82–83, 109, 136
- Epigenetic therapies, path to, 318–321
- Epigenome
broad domains, 191–192
genetic nondeterminism hypothesis, 78
genome altered by, 199
organization, 189–192
organization of transcriptional regulatory events, 163
short regulatory sequences, 189–190
transcription-dependent modifications, 190–191
- Epigenome-wide association study (EWAS)
deficiencies, 315
DNA methylation and, 206–208
harvesting confounders in, 214–217
human disease, 315–316
overview, 3, 206–208
- Epigenome-wide association study (EWAS) design and interpretation
problems
cell subtype proportional composition, 210–212
cohort sizes, 209
genetic effects on DNA methylation, 212–214
reverse causation, 209–210
surrogate tissue sampling, 208–209
- Epigenome-wide studies, fishing expeditions and starting hypotheses in, 163–165
- Epigenomic assays
collections of cells and alleles tested by, 196
colocalization does not mean co-regulation, 196–198
human disease, 315
to using report cellular genomic models, 214–215
using to report DNA sequence effects, 215–217
- Epigenomic data, deconvolution of, 198
- Epigenomic patterns, changes in, 192–195
- Epigenomic pattern transitions, 193–195
- Epigenomics, social, 305
- Epigenomics assays, 163–200, 170–189
chromatin insulation and chromatin looping, 184–185
covalent modifications of RNA, 180
DNA structure variation, 179–180
early, 165–166
histone variants, 183–184
5-methylcytosine and related modifications, 171–179, 172f, 175f, 177f
nucleic acid modifications, 171–180
open chromatin, 182–183
post-translational modifications of histones, 181–182
RNA expression, 186–189
transcription factors, 185–186
- Epigenomic technologies, 6
- Epigenotype, 39, 48–49
- Episignatures, 315
- Epitranscriptomics, 74
- Epstein–Barr virus (EBV), 249
- eQTL (expression quantitative locus), 157, 158f, 159, 161, 216–217, 221, 223
- Equity in research, 313–314, 329
- Erasers of histone PTMs, 109–110
- Essay de Dioptrique* (Hartsoecker), 27–28

- Ethanol, exposure to, 205
Euchromatin, 126–128, 191–192
Eugenics, 227
Euler, Leonhard, 29
EWAS. *See* Epigenome-wide association study
Example study, 1–2, 307–209
Exercises on the Generation of Animals (Harvey), 24, 26
Exonuclease, 186
Exosome, 260, 329
Experiment, made-up, 1–2, 307–309
Expression quantitative locus (eQTL), 157, 158f, 159, 161, 216–217, 221, 223
Extraordinary claims require “extraordinary evidence” (ECREE aphorism), 262, 270
- F**
Fabricius, Hieronymus, 24
FAIRE (formaldehyde-assisted isolation of regulatory elements) assay, 182
Famines, human diseases and, 278–281
FAP (familial adenomatous polyposis), 247
Feed-forward loop, 133
Feinberg, Andy, 228–231
Ferguson-Smith, Anne, 298–299
Field effects, 249–252, 273
Fingerprinting, 166
Fischberg, Michael, 53
Fishing expeditions, 164–165
Flow cytometry, 211
Fluorescein, 155
Fluorescence in situ hybridization (FISH), 185
Folic acid, 205, 219
Formaldehyde cross-linking, 185–186
Formation of the Chicken Heart, On the (Haller), 29–30
Formation of the Intestine, On the (Wolff), 30
Formative Impulse, On the (Blumenbach), 30
- Friend, Charlotte, 255–256
Frommer, Marianne, 169, 173, 232
FTO demethylase, 93–94
Functional genomics assays, 163
Functional variants, 213, 215, 217, 221, 223, 316, 323
Fur color in cats, 147
Fusion genes, 241
- G**
Galen of Pergamon, 21
Galton, Francis, 260
Gardiner-Garden, Margaret, 169, 232
Gedankenexperiment, 129
Gemmules, 260, 293–294
GeMo (genetic monitoring), 295
Generation of Animals, On the (Aristotle), 19, 21
Gene silencing, 233, 244. *See also* Silencing
Genesis, 21
Genetic assimilation, 261, 269
Geneticists, and schism with embryologists, 36–38
Genetic monitoring (GeMo), 295
Genetic nondeterminism, 78
“Gene X Environment” interaction studies, 4
Genome architecture mapping (GAM), 185
Genome-wide association studies (GWASs), 157, 159, 164, 206, 213, 316
Genomic biochemists, rise of, 72–74
Genomic imprinting
Barlow, 70–71
chromatin insulator, 120
Crouse, 53, 56, 67
historical context, 66–71
as physiological, 272
piRNAs, 99
Solter and McGrath, 69–70
targeting events, 134
Genomic organization, 189–192
Genomics, cellular, 160–161
Genotype, Waddington on concept of, 39
- Gerbi, Susan, 66
Germ cell cycle, 296–299, 297f
Glass, Christopher (Chris), 327
Glass, David, 164
GlcNAcylation, 205
Gliomas, 11, 251
Globin gene, 156
Gluckman, Peter, 283
Gluecksohn-Waelsch, Salome, 44
GoldenGate genotyping, 173
G6PD deficiency, X-linked, 65
G-quadruplex, 90, 91f, 179–180
Green, Michael, 238
Guide RNA, 319
Gurdon, John, 53, 56
GWAS. *See* Genome-wide association studies
Gynogenones, 70
- H**
Hackett, Jamie, 302–304
Haemophilus parainfluenzae II (HpaII) restriction enzyme, 232
Haller, Albrecht von, 29–30
Ham, Johan, 27
Haplotypes
DNA methylation, 322–323, 324f–325f, 326
treatment by geneticists, 313
variants within, 157, 221
Harrison, Ross, 37
Hartsoeker, Nicolaas, 27–28
Harvey, William, 20, 21, 24–26
He, Chuan, 93
Heard, Edith, 104
Heat shock locus, 119
HELP assay, 171
Hematoxylin, 154–155
Henikoff, Steven (Steve), 185
Hepatocellular carcinoma, 250–251
Heterochromatin
broad domains, 191–192
constitutive, 127
described, 126–128
gene silencing link, 127–128
history of term, 126
sequence-specific targeting of, 128

- Heterogenous ribonucleoproteins (hnRNPs), 96
- Hi-C assay, 185
- HiFi sequencing, 176, 177f
- Hillman, Nina, 69
- Hippocrates, 18–19
- Histone code, 72, 109–110, 310, 328
- Histone deacetylase (HDAC) inhibition, 205–206
- Histone deacetylase inhibitor (HDACi), 255–256
- Histones
linker, 113–114
modifications, historical context for, 72–73
mRNAs for, 95
post-translational modifications, 95–96, 107–111, 108t, 131, 181–182
- Histone variants, 114–118, 115f, 183–184, 191–192
- Histopathology, 154–156, 160–161, 225
- History of Animals* (Aristotle), 19
- History of epigenetics, 17–49, 309–311
antiquity, 17–20
David Nanney, 46–49
embryology reborn, 24–29
emergence of developmental genetics, 32–36
foundations of modern epigenetics, 5–7
Pugh and Holliday, 53–59, 56f, 62, 73
re-interpretation of epigenetic properties as those of cells, 46–49
Riggs, 59–62
rise of epigenesis, 29–32
rise of genomic biochemists, 72–74
Sager, 52–54
schism between embryologists and geneticists, 36–38
unproductive millennium, 20–23
Waddington, Conrad Hal, 38–46
- HIV (human immunodeficiency virus), 94
- HJURP (Holliday junction recognition protein), 118
- H3K9me3, 192, 199
- H3K27me3, 190, 192, 194, 196–197
- 5hmC modification, 171, 176, 181, 194, 197–198
- hnRNPs (heterogenous ribonucleoproteins), 96
- Hobert, Oliver, 268
- Hodges, Emily, 193
- Holliday, Robin
cancer epigenetics, 56–59, 71
history of epigenetics, 53–59, 56f, 62, 73
photograph, 57f
Pugh and, 53–59, 62, 73
use of epigenetics term, 143
X-inactivation, 84, 143, 228
- Holloman, Bill, 58
- Homeostasis, persistent, 48, 74–75, 76f, 82–83, 203
- Homunculus, 27–28, 28f
- Hongerwinter* (Hunger winter), 279–281
- Hooke, Robert, 27
- Horsthemke, Bernhard, 71, 231–232
- Horvath, Steve, 10
- Houseman, Eugene Andres (Andy), 139–140, 210, 211
- The House of God* (Shem), 103
- Huang, Sui, 302
- Human disease, epigenetics and, 315–318
- Human immunodeficiency virus (HIV), 94
- Huxley, Aldous, 226
- Huxley, Julian, 226–227
- Hypomethylation, in cancers, 231, 236–238
- Hypothesis, starting, 164
- Hypoxia, 205
- I**
- IAP (intracisternal A-particle), 8–9, 145, 277, 298–299, 301
- ICR (imprinting control region), 120
- Identical (monozygotic) twins, 148
- IDH*, 238–240, 242, 251
- IESs (internal eliminated sequences), 101
- Igf2* (insulin-like growth factor 2) gene, 120, 121f
- Igf2r* (insulin-like growth factor type-2 receptor), imprinting of, 71–72
- Ikaros protein, 127
- Illumina microarray system, 173, 174
- Imprinting control region (ICR), 120
- Individual cells, studying, 198–199
- Inheritance of acquired characteristics, 259–262, 310
- Innate* (Mitchell), 315
- Insects, and transgenerational memory, 268–270
- Insulator element, 190
- Insulin-like growth factor 2 (*Igf2*) gene, 120, 121f
- Insulin-like growth factor type-2 receptor (*Igf2r*), imprinting of, 71–72
- Intercellular communications, local, 328
- Intergenerational inheritance, definition, 262–263, 264f
- Intergenerational memory, 272–287
maternal effects, 289–291
paternal effects, 291–293
- Intergenerational nongenetic heritability, how to study, 302–304
- Internal eliminated sequences (IESs), 101
- Interpretability issues, 13
- Intracisternal A-particle (IAP), 8–9, 145, 277, 298–299, 301
- An Introduction to Modern Genetics* (Waddington), 38–40, 44, 49
- Irizarry, Rafa, 193
- IRX3* gene, 94
- ISC (intestinal stem cell), 248

- J**
Jackson, Vaughn, 186
Jaenisch, Rudolf, 72, 104, 237
Janssen, Hans and Zacharias, 26
Jenuwein, Thomas, 72
Jeremiah, 259–260
Job, Book of, 21–22
Johannsen, Wilhelm, 34
John, Bernard, 53
Johnson, D.R., 69
Jones, Peter, 233–235, 255
Junk DNA, 64
- K**
Kant, Immanuel, 31
KDM (lysine demethylase)
inhibitors, 257
Kelsey, Karl, 139–140
Kirkwood, Tom, 54
Kleckner, Nancy, 123
Klinger, Harold, 61
KMT (lysine histone methyltransferase)
inhibitors, 256
Knowles, David, 134
Kofoid, Charles, 225
Krawetz, Stephen, 292–293
Kundakovic, Marija, 218
- L**
lac operon, 59, 60f, 130, 143, 227, 277
Lactylation of histones, 205
LADs (lamin-associated domains), 123, 192, 237
Laird, Peter, 238
Lamarck, Jean-Baptiste, 33, 260
Lamarckism, 3, 45, 310
Lamin-associated domains (LADs), 123, 192, 237
Landau, Dan, 311, 312f
Landscape, epigenetic. *See* Epigenetic landscape
Laplace, Pierre-Simon, 262, 287, 294
Lappalainen, Tuuli, 153
Lee, Jeannie, 105
Leeuwenhoek, Anton van, 27
Leukocytes
composition of populations, 139–140
DNA methylation in, 315–316
sampling in EWAS, 207–212
Levens, David, 133
Lewis, Kenneth Roderick, 53
Li, En, 72
Linker histones, 113–114
L1 LINEs, 99–101
Long noncoding RNAs (lncRNAs), 102–106, 111
Long terminal repeat (LTR)-type TE, 99
Loss-of-function mutation, 230, 231, 244
Lumey, L.H. (Bertie), 283–284
Luria, Salvador, 51
Lyko, Frank, 237, 254
Lyon, Mary, 64–65
Lysenko, Trofim, 261–262
Lysine demethylase (KDM)
inhibitors, 257
Lysine histone methyltransferase (KMT) inhibitors, 256
- M**
MacroH2A, 183–184
MAFG protein, 238–239
Maintenance methylation, 54–55, 57, 59, 62, 65, 83, 228, 236, 267
Maize pigmentation, 265, 266f
Malleability, 4, 12
Malpighi, Marcello, 27
Mangold, Hilde, 36
Manx cats, 33
MAO inhibitors, 257
MARE (Maf recognition element), 239
MAPK (mitogen-activated protein kinase), 246
Markov-chain entropy (MCE), 322
Marsit, Carmen, 139–140
Maternal effects, 289–291
Mating type choice in *Tetrahymena*, 46–48
MBD4, 167
MCA (methylated CpG island amplification), 233
McCance, Robert, 278
McClintock, Barbara, 67, 263–264
MCE (Markov-chain entropy), 322
McGrath, Jim, 69–70
Meaney, Michael, 274, 290–291
MeDIP (methylated DNA immunoprecipitation), 172, 174, 178, 271
Meehan, Richard, 124, 191
Meissner, Alex, 193
Mello, Craig, 267–268
Melting temperature, 227–228
Memory
inheritance of acquired characteristics, 259–262
inheriting memories, 259–306
intergenerational, 262–263, 264f, 272–287
maternal effects, 289–291
molecular mechanisms in humans, 287–304
paternal effects, 291–293
transgenerational, 263–272, 264f, 305–306
Mendel, Gregor, 32, 33
Mendel's Principles of Heredity: A Defence (Bateson), 33–34
meQTL (methylation quantitative trait locus), 213, 216–217, 220
Metz, Charles, 66–67
Metamorphosis, 25, 26
Metastable epialleles, 144–146, 146f, 277, 299
Methyladenine, 183
6-methyladenosine (6mA), 89, 93–94, 176, 180, 197–198, 322–323
Methylated CpG island amplification (MCA), 233
Methylated DNA
immunoprecipitation (MeDIP), 172, 174, 178, 271
Methylation
differential, 165–166
DNA (*see* DNA methylation)
histone, 95–96, 110
maintenance, 54–55, 57, 59, 62, 65, 83, 228, 236, 267
RNA, 93–94
Methylation quantitative trait locus (meQTL), 213, 216–217, 220

- Methylation risk scores, 318, 330
- 5-methylcytosine (5mC)
epigenomic assays, 171–179
5mC cycle, 83–89, 85f, 88f
in XP12 phage, 227
- Methyltransferases, 93
- Metius, Jacob, 26
- Mice
metastable epialleles, 144–146, 146f
viable yellow mice, 8, 145–146, 146f, 277, 298–299, 301, 309, 314
- Microarrays, 166, 170–171, 173–174, 176, 184–191
- Micro-C assay, 124, 125f, 185
- Micrococcal nuclease (MNase), 181
- Micrographia* (Hooke), 27
- MicroRNA (miRNA), 93, 98
- Microscope, history of
development, 26–27
- Minute group of genes, 40
- miRNAs, 93, 98
- Mirny, Leonid, 124
- Missing heritability, 4
- Mitchell, Kevin, 295–296, 296f, 315
- Mitotic bookmark, 133
- MNase, 185
- Molecular genomic assays
as biomarkers, 329
human disease, 315–316
- Molecular genomic regulatory mediators, 288–289
- Molecular mechanisms of epigenetic properties, 81–137
cooperative system for cellular memory, 136–137
functional RNAs, 97–106
properties of epigenetic regulators, 81–83
transcription, 135
transcription factors, 129–134
variability of chromatin, 106–128
variability of DNA, 83–92
variability of RNA, 93–97
- Molecular memory, by DNA methylation, 54–55, 59, 62
- Molecular quantitative trait loci (molQTLs), 313
- Momme*, 145, 314–315
- Monk, Marilyn, 204
- Monocytes, 157
- Monod, Jacques, 59, 60f
- Monozygotic twins, 3–4
- Morgan, Thomas Hunt, 34–36
- Morphogenesis, 142, 151
- Morphogen gradients, 218
- Mosaicism, 196, 197, 203, 222
- mRNA
for histone proteins, 95
methylation, 93
- mRNA-seq, 187
- Muller, Hermann Joseph, 127, 143, 314, 323
- Multigenerational memory, 75, 76f, 78
- Multigenerational nongenetic heritability
implications of, 295–296
problem of using outbred animals, 294–295
theory, 294
unintended negative consequences of field, 305–306
- Multi-omics, 321
- Murine metastable epialleles (*Mommes*), 145, 314–315
- Mutation(s)
altering the differentiation of cells, 156–157
causing local changes of epigenetic regulation, 243
causing metabolic effects with secondary epigenetic effects, 242
cell fate changed by, 156
as primary event in cancer epigenomes, 240–244
as primary event in epigenetic mechanisms of disease, 203
of transcriptional regulators, 241–242
- Myelodysplastic syndrome, 12
- MyoD1*, 235
- N**
- NAD (nicotinamide adenine dinucleotide), 205
- Nanney, David
cellular memory, 149, 152
paragenetic (term), 47
persistent homeostasis, 48, 82–83, 203
plasmagene hypothesis, 102
re-interpretation of epigenetic properties of cells, 46–49
Tetrahymena, 46–48, 101
use of epigenetic term, 47–49, 51, 62, 156
- Nanopore sequencing, 176, 177f
- Navarro, Pablo, 133
- ncRNAs, 190
- Needham, Dorothy Moyle, 38
- Needham, Joseph, 38
- Neuron-restrictive silencer factor (NRSF), 190
- Neuropeptide F (NPF), 270
- Neutropenia, benign ethnic, 157
- Nicotinamide adenine dinucleotide (NAD), 205
- nonagouti* locus, 8–9, 277, 309
- Noncoding (nc) RNA, 97, 190
- Normalization, 178, 189
- NotI, 165
- NPF (neuropeptide F), 270
- Nr3c1* gene, 274, 275f
- NRSF (neuron-restrictive silencer factor), 190
- Nuclear transfer, 53, 56
- Nucleic acid modifications, epigenomic assays of, 171–180
- Nucleolar satellite, 63
- Nucleosomal positioning, 111–114
- Nucleosome-remodeling complexes, 112–113
- Nucleosomes
histones, 95
number of, 107
open chromatin, 182
paternal effects, 292
transcription factors and displacement, 131–132
- Weintraub, 106

- O**
- Obesity, 2, 94, 210, 215, 220, 248, 281, 286–287, 307, 315, 317–318
 - Ohno, Susumu, 59, 61, 63–64
 - Olfactory receptor genes, 112
 - Oligonucleotide of thymine (oligo-dT), 187
 - Oncometabolite, 242
 - Oocyte imprinting, 289
 - Open chromatin, 182–183, 190, 218, 222
 - Organisers and Genes* (Waddington), 40, 42
 - Organizer, 36, 38–39, 44, 218
 - Origin of Species, On the* (Darwin), 32, 260
 - Outbred animals, problem of using, 294–295
 - Ovism, 27–28, 310
- P**
- Paneth, Nigel, 282–283
 - Pangenesis, 260
 - Paradigms in epigenetics
 - cancer epigenetics, 71–72
 - cigarette smoking, 9–10
 - epigenetic clock CpGs, 10–11
 - genomic imprinting, 66–71
 - gliomas, 11
 - viable yellow mouse, 8–9
 - X-chromosome inactivation, 62–65
 - Paramutation, 7, 265–267, 266f
 - Parent-of-origin effect, 67, 69–71
 - Partially methylated domains (PMDs), 192
 - Particulate theory of development, 35
 - Paternal effects, 291–293
 - PCR duplicates, 178
 - PDGFRA* gene, 11, 251
 - Peripheral blood leukocytes
 - DNA methylation in, 315–316
 - sampling in EWAS, 207–212
 - Peroxisome proliferator activated receptors (PPARs), 320
 - Persistent homeostasis, 48, 74–75, 76f, 82–83, 203
 - PGCs (primordial germ cells), 297
 - Phase separation, 128
 - Phenotype, Waddington on
 - concept of, 39
 - Pigmentation in mice, 298, 301
 - Pioneer transcription factor (TF) model, 132, 132f
 - Piper, John, 40, 41f, 311
 - piRNAs, 99, 101
 - Plantade, François de, 27
 - Plants
 - cytosine methylation, 84
 - DNA methylation, 174
 - organization of genes and heterochromatin, 83
 - transgenerational memory, 263, 265–267, 266f
 - Plasmagene, 47, 102
 - Plasterk, Ronald, 267
 - PMDs (partially methylated domains), 192
 - Polyadenylation, 95, 187
 - Polycomb, 105, 111, 114, 124, 128, 133, 136, 170, 194, 195, 291, 308
 - Polycomb-response elements (PREs), 128
 - Polycyroidism, 153–154, 156, 159–160, 214, 218
 - Polymorphism, 153, 160, 165
 - Pontecorvo, Guido, 47
 - Position-effect variegation, 127, 143–144, 314
 - Post-translational modifications (PTMs)
 - of histones, 95–96, 107–111, 108t, 131, 181–182
 - of transcription factors, 328
 - PPARs (peroxisome proliferator activated receptors), 320
 - Precision nuclear run-on sequencing (PRO-seq) assay, 188
 - Preformationism
 - Aristotle's rejection of, 20
 - Blumenbach, 30–31
 - Haller's defense of, 29–30
 - Harvey, 25
 - Hippocrates, 18
 - Kant on, 31
 - ovist model of, 27–28
 - preformationism *versus* epigenesis question, 29–32, 310
 - Swammerdam, 26
 - Wolff, 29–30
 - PREs (Polycomb-response elements), 128
 - Primordial germ cells (PGCs), 297
 - Prochiantz, Alain, 328
 - Promoter
 - characteristics, 189
 - DNA methylation studies, 230–231, 233
 - H3K27me3 mark, 189, 194
 - mapping, 190
 - methylation, 254, 274
 - mutations, 243
 - in transcription process, 191
 - Promyelocytic leukemia (PML), acute, 318–319, 320f
 - PRO-seq (precision nuclear run-on sequencing) assay, 188
 - Pseudoagouti, 298, 301
 - Pseudoscience, 78
 - Pseudoscientific health products, 148–149
 - Ptashne, Mark, 130
 - PTMs. *See* Post-translational modifications
 - Pugh, John
 - history of epigenetics, 53–59, 56f, 62, 73, 89, 103
 - photograph, 57f
 - use of epigenetics term, 56–59, 56f, 73, 143
 - X-chromosome inactivation, 53–54, 56, 58, 61–62, 84
 - X-inactivation, 228
 - Pythagoras, 18
- Q**
- Quantitative trait locus (QTL)
 - cell count QTL (ccQTL), 159, 161
 - chromatin QTL (cQTL), 221
 - expression (eQTL), 157, 158f, 159, 161, 216–217, 221, 223

- Quantitative trait locus (QTL)
(*Continued*)
methylation (meQTL), 213,
216–217, 220
molecular (molQTL), 313
Question/model paradigm,
164
Qu'ran, 22
- R**
Rabl, Carl, 122
Rando, Oliver (Ollie), 110,
292–294, 300
RARA protein, 319, 320f
Rasgrfl gene, 99
Rat maternal nurturing model,
274, 290–291
RBI (retinoblastoma gene),
231–232
R chromatin, 132, 133
RdDM (RNA-directed DNA
methylation), 98–99, 267
RdRP (RNA-dependent RNA
polymerases), 266–268
Reaction theory, 35
Readers of histone PTMs,
109–110, 128
Rechavi, Oded, 268
Religious texts, 22
Replication, 223
Repressive marks, 194
RE1-silencing transcription
factor (REST), 190
Response eQTL, 216–217
REST (RE1-silencing
transcription factor), 190
Restriction enzyme, 89–90
Restriction landmark genomic
scanning (RLGS), 165
Restriction-modification
systems
Chlamydomonas, 52, 54,
89, 230
described, 89–90
Monk, 51
reason for interest in, 55f
Sager, 52, 54, 84, 89, 230
Retinoblastoma (*RBI*),
231–232
Retinoic acid signaling,
150–152
Reverse causation, 209–210
Reversibility, 303, 309
5-ribosyluracil, 93
Ribozyme, 104
Richmond, Tim, 109
Riggs, Arthur (Art)
Boyer and, 59, 61, 90, 103
epigenetic (term), 61–62
epigenetics definition, 74–75
history of epigenetics, 59–62
on Ohno, 64
passing of, 310
on Waddington, 61–62
X-inactivation, 59, 61, 84,
228
RLGS (restriction landmark
genomic scanning), 165
RLGS-M (methylation), 165,
171
R-loop, 90, 91f, 319
RNA
chromatin-associated, 96
covalent modifications,
93–94, 180
dsRNA, 268
enhancer RNAs (eRNAs),
190–191, 213
folding, 104–105
functional RNAs, 97–106
guide, 319
localization, 96
long noncoding RNAs
(lncRNAs), 102–106,
111
methylation, 93–94
miRNAs, 93, 98
noncoding (nc), 97, 190
piRNAs, 99, 101
production timing, 95
scan RNAs (scnRNAs),
101–102
sequencing, 187–188
small interfering (siRNA),
98, 265–267, 266f
small nuclear RNA
(snRNA), 96
splicing, 95–96
variability, 93–97
RNA degradation, 188
RNA-dependent RNA
polymerases (RdRP),
266–268
RNA-directed DNA
methylation (RdDM),
98–99, 267
RNA:DNA hybrids, 179–180,
187
RNA expression, 186–189
RNA immunoprecipitation
(RIP), 180
RNA interference (RNAi)
in *Caenorhabditis elegans*,
267–268
siRNAs, 98, 265
RNA polymerase, 135, 190–191
RNA-seq, 222
Robinson, Wendy, 236
Rodents, transgenerational
memory in, 270–271
Russell, Liane, 65, 144
- S**
S-adenosyl methionine (SAM),
205
Sagan, Carl, 262, 287, 294
Sager, Ruth, 52–54, 84, 89,
103, 230
SAHA (suberoylanilide
hydroxamic acid), 256
Sasaki, Hiro, 99, 147
SBHA (suberic bishydroxamic
acid), 256
Scan RNAs (scnRNAs),
101–102
scATAC-seq, 321
Schedl, Paul, 119
Schizopneuria, 281
Schübeler, Dirk, 194
Sciara coprophila, 5, 53, 66–67,
68f, 71
scRNA-seq (single-cell RNA-
seq), 321
Semantics, 1–2
SEPT9 gene, 253
Sequencing
emerging technologies,
322–323
long-read, 322–323,
324f–325f
Sequencing-based, 170–171.
*See also specific
applications*
Serotonin, 205
Sex chromatin, 63–65
Sex determination
environmental regulation
of, 38
genetic mechanism for, 36

- Sharp, Gemma, 305
Shem, Samuel, 103
Shiota, Kunio, 165
Short interfering RNAs (siRNAs), 98, 265–267, 266f
Short regulatory sequences, 189–190
Sickle cell disease, 156
Signal transfers, 328–329
Silencers, 190
Silencing
 in *C. elegans*, 267–268
 of chromatin by small RNAs, 293
 heterochromatin link to, 127–128
 miRNAs, 98
 piRNAs, 99, 101
 siRNAs, 98
 of transposable elements, 127
 XIST, 104–105
Singer, Rob, 135
Single-cell genome-wide assays, 140
Single-cell platforms, 321–322
Single-cell RNA-seq (scRNA-seq), 321
Single-cell studies, 211
Single-nucleotide polymorphisms (SNPs), 173, 179, 212–213
siRNA (small interfering RNA), 98, 265–267, 266f
Skinner, Michael, 270–271
Small nuclear RNAs (snRNAs), 96
Small RNAs, 188, 292–293, 300, 328–329
Small ubiquitin-related modifier (SUMO), 107
Smith, Clement, 278–280
Smoking, 204, 207, 220, 290
Snell, George, 69–70
SNP microarray, 173
SNPs (single-nucleotide polymorphisms), 173, 179, 212–213
Snyder, Michael (Mike), 166, 323
Sodium bisulfite conversion of DNA, 173–179, 175f
Soloway, Paul, 196
Solter, Davor, 69–70
Sonneborn, Tracy, 47–48
Sotos syndrome, 315
Southern, Edwin (Ed), 232
Spatial transcriptomics, 199
Spemann, Hans, 36, 38, 44, 218
Sperm
 DNA methylation, 299–300
 small RNAs in, 292–293, 300
Spermatogenesis, effect of vinclozolin on rodents, 270–271
Sperm competition, 300
Spermism, 28, 310
Splicing, 95–96, 187, 189
Stability
 chromatin insulation, 121
 DNA conformation, 92
 functional RNA, 106
 heterochromatin, 128
 histone PTMs, 111
 histone variants, 118
 linker histones and nucleosome positioning, 114
 5-methylcytosine, 92
 property of epigenetic regulators, 82–83
 RNA modifications, 97
 small RNAs, 102
 TADs, 126
Steensel, Bas van, 123, 192
Stein, Zena, 280–281, 284–285
Stevens, Nettie, 36
Strahl, Brian, 72, 109
The Strategy of the Genes: A Discussion of Some Aspects of Theoretical Biology (Waddington), 41–42, 44–45
Sturtevant, Alfred, 38–39
Suberoylanilide hydroxamic acid (SAHA), 256
Summa Theologica (Thomas Aquinas), 22
SUMO (small ubiquitin-related modifier), 107
Suppressor of variegation (Su(var)) genes, 127
Surani, Azim, 70, 297–298, 302, 304, 321
Surrogate tissue sampling, 208–209
Surrogate variable analysis (SVA), 212
Sushruta, 17–18, 22
Susser, Ezra, 281
Susser, Mervyn, 280–283, 285
Sutton, Walter, 34, 122
SVA (surrogate variable analysis), 212
Swammerdam, Jan, 26–27
SWI/SNF enzymes, 112–113
T
Taderera, Joseph, 234–235
TADs (topologically associating domains), 124, 126
Talmud, 21–22
TAL1 oncogene, 243
Targeting
 chromatin insulation, 121
 DNA methylation, 92
 heterochromatin, 128
 histone PTMs, 111
 histone variants, 118
 linker histones and nucleosome positioning, 114
 long noncoding RNAs, 106
 property of epigenetic regulators, 82–83
 RNA modifications, 97
 small RNAs, 102
 TADs, 126
 transcription factors, 134
T-associated maternal effect (Tme), 70–71
TATA box, 133, 135
TDGs (thymine DNA glycosylases), 87–88
tDMR (tissue differentially methylated region), 165
Technologies, emerging, 321–326
Telomerase reverse transcriptase (*TERT*) gene, 243
Teratogenicity, 272–273
TEs. *See* Transposable elements
TET (ten-eleven translocation) enzymes, 87–88, 194, 198, 205, 236, 238, 242

- Tetrahymena*, 46–48, 72, 101
TFs. *See* Transcription factors
Theoria generationis (Wolff), 29
Thrifty phenotype hypothesis, 282–283
Thymine, 167, 168f, 173, 174f, 175, 178, 252
Thymine DNA glycosylases (TDGs), 87–88
Tilghman, Shirley, 120, 277
Tissue differentially methylated region (tDMR), 165
Tissue sampling, 220–221
T-locus mutations, 33
Tme (T-associated maternal effect), 70–71
Topologically associating domains (TADs), 124, 126
Tortoiseshell cats, 147
Towards a Theoretical Biology (Waddington), 142
Transcription, 135
Transcriptional regulators, mutations in, 241–242
Transcriptional regulatory mechanisms, cancer therapies directed at, 255–257
Transcription-dependent modifications, 190–191
Transcription factors (TFs), 129–134
assays, 185–186
cancer dormancy, 246
cell fate decisions, 131, 134
cellular epigenetic changes, memory, and phenotypes, 217–219
changing binding patterns, 193
defined, 130
domains, 130–131
epigenetic therapies, 319–321
exchange of, 328
feed-forward loops, 133
mapping binding sites, 166
mitotic bookmarks, 133
nucleosome displacement, 131
open chromatin, 182
pioneer model, 132, 132f
PTMs, 328
repressive activities, 190
variability of binding, 327
trans eQTL, 159, 216
Transgenerational inheritance, and potential to do harm, 305–306
Transgenerational memory, 263–272
Caenorhabditis elegans, 267–268
definition, 263, 264f
insects, 268–270
paramutation, 265–267, 266f
plants, 263, 265–267, 266f
rodents, 270–271
Transposable elements (TEs)
Barbara McClintock, 265
cancer epigenetics, 237, 240
CG dinucleotides, 169–170
classes, 100f
IAP (intracisternal A-particle), 8–9, 145, 277, 298–299, 301
piRNAs and, 99–101
reactivation of, 12
silencing of, 127
Transposase, 182–183
Tremellaceae, 87
Trim28, 315
Tumor-suppressor genes, 52, 73, 77, 230, 231, 244, 249
Two-dimensional electrophoresis, 165
U
UHRF1, 85–86
Uracil, 167, 168f, 173, 174f, 252
Uracil-DNA-glycosylase (UDG), 187
Ustilago maydis, 53, 58
V
van der Meulen, Jan, 284
Vanyushin, Boris, 228–229
Variability of DNA, 83–92
Variability of RNA, 93–97
The Variation of Animals and Plants under Domestication (Darwin), 260
Verification, 223
Viable yellow mice, 8, 145–146, 146f, 277, 298–299, 301, 309, 314
Vinclozolin, 270–271, 296
Viruses, oncogenic, 248–249
Vitamin A, 150–151, 153
Vogelstein, Bert, 229–231
von Haller, Albrecht, 310
W
Waddington, Conrad Hal
acquired heritability, 260–261, 269
cell fate decisions, 82
epigenetic landscape, 61, 74, 76f, 142, 144, 149, 153, 156, 247, 301, 311, 314–315, 322
epigenetic properties as those of cells and tissues, 143
epigenetics definition, 73–75, 76f
epigenotype term, 39, 48–49
genetic assimilation, 261, 269
history of epigenetics, 14–15, 38–46
last word, 142–143
Lyon on, 65
morphogenesis, 142, 151
Principles of Embryology, 226
Riggs on, 61–62
Waldeyer-Hartz, Heinrich Wilhelm von, 154
Wang, Zhen-Yi, 319
Weintraub, Harold (Hal), 106–107, 235
Weismann, August, 33, 310
Weksberg, Rosanna, 317
white gene, 143–144, 314, 323
Whitelaw, Emma, 8, 145, 298, 314
Whole-cell RNA profiles, 188
Whole-genome bisulfite sequencing (WGBS), 193, 222
Whole-genome sequencing, 322
Widdowson, Elsie, 278
Wiencke, John, 139–140
Willard, Huntington (Hunt), 103–104

- Wilson, Edmund Beecher, 36
Window of susceptibility, 204
Wolff, Caspar Friedrich,
29–30, 310
Wolff, George, 8–9, 298
Writer of histone PTMs, 110,
128
WXYZI gene, 157
- X**
X-chromosome, inactive
Barr body, 64, 127
DXZ4 sequence, 126
X-chromosome inactivation
Barr and Bertram, 62–64
chromosome territory, 123
fur color in cats, 147
genes escaping, 123
historical context, 62–65
Holliday, 84, 143, 228
Lyon, 64–65
molecular mechanism,
146–147
Ohno, 59, 61, 63–64
Pugh, 53–54, 56, 58, 61–62,
84
reactivation of genes on the
silent X chromosome, 72
Riggs, 59, 61, 84, 228
Sager, 52
targeting events, 134
variation in outcomes, 315
Willard and Brown,
103–104
X inactive-specific transcript
(*XIST*), 96, 103–105, 105f
XIST (X inactive-specific
transcript), 96, 103–105,
105f
X-linked G6PD deficiency, 65
- Y**
Young, Rick, 166
YY1, 190
- Z**
Zaret, Ken, 131–132, 133
Zedong, Mao, 261
Zeng, Hongkui, 330
Žernicka-Goetz, Magdalena,
302